Philippe Halfon

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Durant, Philippe Clevenbergh, Philippe Halfon et al. · The Lancet · 1999 · 762 citations

Life Sciences, Pharmacotherapy, Molecular Virology +15

CpG Methylation Controls Reactivation of HIV from Latency

Jana Blažková, Kateřina Trejbalová, Françoise Gondois‐Rey et al. · PLoS Pathogens · 2009 · 327 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

CMV drives clonal expansion of NKG2C ⁺ NK cells expressing self‐specific KIRs in chronic hepatitis patients

Vivien Béziat, Olav Dalgård, Tarik Asselah et al. · European Journal of Immunology · 2011 · 274 citations

Life Sciences, Immunology, Infectious Diseases +17

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Thierry Poynard, Philippe Halfon, Laurent Castéra et al. · Clinical Chemistry · 2007 · 238 citations

Medicine, Clinical Sciences, Pathology +17

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Durant, Philippe Clevenbergh, R. Garraffo et al. · AIDS · 2000 · 223 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17